This roundtable series examines therapeutic options for patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer, as discussed by key opinion leaders and participants at virtual live events.
Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLC
January 2nd 2024Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.
Velcheti Addresses Promising Data with Repotrectinib in ROS1+ NSCLC
February 20th 2024In the first article of a 2-part series, Vamsidhar Velcheti, MD, MBA, discussed why patients with lung cancer may experience dizziness with repotrectinib and why the efficacy data behind this therapy are considered impressive.